Global Peripherally Acting Anti-Obesity Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Get Access Now!

Global Peripherally Acting Anti-Obesity Drug Market Growth Status and Outlook 2025-2031

The global Peripherally Acting Anti-Obesity Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. A Peripherally Acting Anti-Obesity Drug is a medication designed to treat obesity by acting on the peripheral nervous system or other systems in the body. These drugs target various mechanisms involved in appetite regulation, metabolism, and fat absorption to aid in weight loss. United States market for Peripherally Acting Anti-Obesity Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. China market for Peripherally Acting Anti-Obesity Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Europe market for Peripherally Acting Anti-Obesity Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Global key Peripherally Acting Anti-Obesity Drug players cover Novo Nordisk A/S, Pfizer Inc., Boehringer Ingelheim International GmbH, KVK Tech Inc., Gelesis Holdings, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024. Infinity Market Research newest research report, the Peripherally Acting Anti-Obesity Drug Industry Forecast looks at past sales and reviews total world Peripherally Acting Anti-Obesity Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Peripherally Acting Anti-Obesity Drug sales for 2025 through 2031. With Peripherally Acting Anti-Obesity Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peripherally Acting Anti-Obesity Drug industry. This Insight Report provides a comprehensive analysis of the global Peripherally Acting Anti-Obesity Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Peripherally Acting Anti-Obesity Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Peripherally Acting Anti-Obesity Drug market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peripherally Acting Anti-Obesity Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peripherally Acting Anti-Obesity Drug. This report presents a comprehensive overview, market shares, and growth opportunities of Peripherally Acting Anti-Obesity Drug market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Prescription Drugs &nbsp;&nbsp;&nbsp; Non-prescription Drugs Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital Pharmacies &nbsp;&nbsp;&nbsp; Retail Pharmacies &nbsp;&nbsp;&nbsp; Online Pharmacies This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Novo Nordisk A/S &nbsp;&nbsp;&nbsp; Pfizer Inc. &nbsp;&nbsp;&nbsp; Boehringer Ingelheim International GmbH &nbsp;&nbsp;&nbsp; KVK Tech Inc. &nbsp;&nbsp;&nbsp; Gelesis Holdings &nbsp;&nbsp;&nbsp; Vivus LLC. &nbsp;&nbsp;&nbsp; Currax Pharmaceuticals LLC &nbsp;&nbsp;&nbsp; GlaxoSmithKline plc &nbsp;&nbsp;&nbsp; CHEPLAPHARM Arzneimittel GmbH &nbsp;&nbsp;&nbsp; Rhythm Pharmaceuticals Key Questions Addressed in this Report What is the 10-year outlook for the global Peripherally Acting Anti-Obesity Drug market? What factors are driving Peripherally Acting Anti-Obesity Drug market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Peripherally Acting Anti-Obesity Drug market opportunities vary by end market size? How does Peripherally Acting Anti-Obesity Drug break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Peripherally Acting Anti-Obesity Drug Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Peripherally Acting Anti-Obesity Drug by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Peripherally Acting Anti-Obesity Drug by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Peripherally Acting Anti-Obesity Drug Segment by Type &nbsp;2.2.1 Prescription Drugs &nbsp;2.2.2 Non-prescription Drugs &nbsp;2.3 Peripherally Acting Anti-Obesity Drug Sales by Type &nbsp;2.3.1 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Peripherally Acting Anti-Obesity Drug Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Peripherally Acting Anti-Obesity Drug Sale Price by Type (2020-2025) &nbsp;2.4 Peripherally Acting Anti-Obesity Drug Segment by Application &nbsp;2.4.1 Hospital Pharmacies &nbsp;2.4.2 Retail Pharmacies &nbsp;2.4.3 Online Pharmacies &nbsp;2.5 Peripherally Acting Anti-Obesity Drug Sales by Application &nbsp;2.5.1 Global Peripherally Acting Anti-Obesity Drug Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Peripherally Acting Anti-Obesity Drug Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Peripherally Acting Anti-Obesity Drug Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Peripherally Acting Anti-Obesity Drug Breakdown Data by Company &nbsp;3.1.1 Global Peripherally Acting Anti-Obesity Drug Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Peripherally Acting Anti-Obesity Drug Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Company (2020-2025) &nbsp;3.2.2 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Peripherally Acting Anti-Obesity Drug Sale Price by Company &nbsp;3.4 Key Manufacturers Peripherally Acting Anti-Obesity Drug Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Peripherally Acting Anti-Obesity Drug Product Location Distribution &nbsp;3.4.2 Players Peripherally Acting Anti-Obesity Drug Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Peripherally Acting Anti-Obesity Drug by Geographic Region &nbsp;4.1 World Historic Peripherally Acting Anti-Obesity Drug Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Peripherally Acting Anti-Obesity Drug Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Peripherally Acting Anti-Obesity Drug Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Peripherally Acting Anti-Obesity Drug Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Peripherally Acting Anti-Obesity Drug Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Peripherally Acting Anti-Obesity Drug Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Peripherally Acting Anti-Obesity Drug Sales Growth &nbsp;4.4 APAC Peripherally Acting Anti-Obesity Drug Sales Growth &nbsp;4.5 Europe Peripherally Acting Anti-Obesity Drug Sales Growth &nbsp;4.6 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Growth 5 Americas &nbsp;5.1 Americas Peripherally Acting Anti-Obesity Drug Sales by Country &nbsp;5.1.1 Americas Peripherally Acting Anti-Obesity Drug Sales by Country (2020-2025) &nbsp;5.1.2 Americas Peripherally Acting Anti-Obesity Drug Revenue by Country (2020-2025) &nbsp;5.2 Americas Peripherally Acting Anti-Obesity Drug Sales by Type (2020-2025) &nbsp;5.3 Americas Peripherally Acting Anti-Obesity Drug Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Peripherally Acting Anti-Obesity Drug Sales by Region &nbsp;6.1.1 APAC Peripherally Acting Anti-Obesity Drug Sales by Region (2020-2025) &nbsp;6.1.2 APAC Peripherally Acting Anti-Obesity Drug Revenue by Region (2020-2025) &nbsp;6.2 APAC Peripherally Acting Anti-Obesity Drug Sales by Type (2020-2025) &nbsp;6.3 APAC Peripherally Acting Anti-Obesity Drug Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Peripherally Acting Anti-Obesity Drug by Country &nbsp;7.1.1 Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2020-2025) &nbsp;7.1.2 Europe Peripherally Acting Anti-Obesity Drug Revenue by Country (2020-2025) &nbsp;7.2 Europe Peripherally Acting Anti-Obesity Drug Sales by Type (2020-2025) &nbsp;7.3 Europe Peripherally Acting Anti-Obesity Drug Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Peripherally Acting Anti-Obesity Drug by Country &nbsp;8.1.1 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Peripherally Acting Anti-Obesity Drug &nbsp;10.3 Manufacturing Process Analysis of Peripherally Acting Anti-Obesity Drug &nbsp;10.4 Industry Chain Structure of Peripherally Acting Anti-Obesity Drug 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Peripherally Acting Anti-Obesity Drug Distributors &nbsp;11.3 Peripherally Acting Anti-Obesity Drug Customer 12 World Forecast Review for Peripherally Acting Anti-Obesity Drug by Geographic Region &nbsp;12.1 Global Peripherally Acting Anti-Obesity Drug Market Size Forecast by Region &nbsp;12.1.1 Global Peripherally Acting Anti-Obesity Drug Forecast by Region (2026-2031) &nbsp;12.1.2 Global Peripherally Acting Anti-Obesity Drug Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Peripherally Acting Anti-Obesity Drug Forecast by Type (2026-2031) &nbsp;12.7 Global Peripherally Acting Anti-Obesity Drug Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Novo Nordisk A/S &nbsp;13.1.1 Novo Nordisk A/S Company Information &nbsp;13.1.2 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications &nbsp;13.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Novo Nordisk A/S Main Business Overview &nbsp;13.1.5 Novo Nordisk A/S Latest Developments &nbsp;13.2 Pfizer Inc. &nbsp;13.2.1 Pfizer Inc. Company Information &nbsp;13.2.2 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications &nbsp;13.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Pfizer Inc. Main Business Overview &nbsp;13.2.5 Pfizer Inc. Latest Developments &nbsp;13.3 Boehringer Ingelheim International GmbH &nbsp;13.3.1 Boehringer Ingelheim International GmbH Company Information &nbsp;13.3.2 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications &nbsp;13.3.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Boehringer Ingelheim International GmbH Main Business Overview &nbsp;13.3.5 Boehringer Ingelheim International GmbH Latest Developments &nbsp;13.4 KVK Tech Inc. &nbsp;13.4.1 KVK Tech Inc. Company Information &nbsp;13.4.2 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications &nbsp;13.4.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 KVK Tech Inc. Main Business Overview &nbsp;13.4.5 KVK Tech Inc. Latest Developments &nbsp;13.5 Gelesis Holdings &nbsp;13.5.1 Gelesis Holdings Company Information &nbsp;13.5.2 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications &nbsp;13.5.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Gelesis Holdings Main Business Overview &nbsp;13.5.5 Gelesis Holdings Latest Developments &nbsp;13.6 Vivus LLC. &nbsp;13.6.1 Vivus LLC. Company Information &nbsp;13.6.2 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications &nbsp;13.6.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Vivus LLC. Main Business Overview &nbsp;13.6.5 Vivus LLC. Latest Developments &nbsp;13.7 Currax Pharmaceuticals LLC &nbsp;13.7.1 Currax Pharmaceuticals LLC Company Information &nbsp;13.7.2 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications &nbsp;13.7.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Currax Pharmaceuticals LLC Main Business Overview &nbsp;13.7.5 Currax Pharmaceuticals LLC Latest Developments &nbsp;13.8 GlaxoSmithKline plc &nbsp;13.8.1 GlaxoSmithKline plc Company Information &nbsp;13.8.2 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications &nbsp;13.8.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 GlaxoSmithKline plc Main Business Overview &nbsp;13.8.5 GlaxoSmithKline plc Latest Developments &nbsp;13.9 CHEPLAPHARM Arzneimittel GmbH &nbsp;13.9.1 CHEPLAPHARM Arzneimittel GmbH Company Information &nbsp;13.9.2 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications &nbsp;13.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 CHEPLAPHARM Arzneimittel GmbH Main Business Overview &nbsp;13.9.5 CHEPLAPHARM Arzneimittel GmbH Latest Developments &nbsp;13.10 Rhythm Pharmaceuticals &nbsp;13.10.1 Rhythm Pharmaceuticals Company Information &nbsp;13.10.2 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications &nbsp;13.10.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Rhythm Pharmaceuticals Main Business Overview &nbsp;13.10.5 Rhythm Pharmaceuticals Latest Developments 14 Research Findings and Conclusion

Report	Global Peripherally Acting Anti-Obesity Drug Market Growth 2025-2031
Selected License	Multi ID: LPI35531

Buyer Information

Order Summary